Thermo Fisher Scientific Inc. (TMO)
SEC filings, financial facts, source resources, and Goglides workspace context for Thermo Fisher Scientific Inc..
OpenSearch
Find research, discussions, posts, companies, and topics.
Search uses Goglides API results from the projection-backed discovery index. Private, draft, hidden, unpublished, and admin-only content stays out of public results.
4Results1Tickers
Refine results
Recent Searches
Signed-in searches appear here after you use search.
Trending
XORTX Therapeutics Inc.: the filing proof gates that matter nowWilliams Companies: natural-gas infrastructure cash flow has to outlast capex and rate riskAurora Cannabis (ACB): the medical-cannabis turnaround trying to outrun dilutionAbbVie Inc. (ABBV) Coverage Bootstrap: Skyrizi and Rinvoq-led biopharma transition after HumiraAmbev (ABEV) Coverage Bootstrap: beer-led scale, Brazil execution, pricing discipline, and cash returnsAsbury Automotive Group (ABG) Coverage Bootstrap: dealership scale, service profit, F&I scrutiny, and leverage disciplineAble View Global (ABLV) Coverage Bootstrap: China beauty brand management, channel concentration, controlled voting, and listing riskABM Industries (ABM) Coverage Bootstrap: facility services scale, margin recovery, WGNSTAR integration, and labor execution
Top Tickers
Popular Tags
Tag facets appear after tag usage counts are rebuilt.
Results
Save searchLatest indexed results
Showing public results only.
Thermo Fisher: Can inorganic M&A growth sustain the premium earnings multiple today?
Thermo Fisher's acquisition engine is still powerful, but Q1 2026 showed why the premium-multiple debate needs a harder evidence gate: 6% reported revenue growth, 1% organic growth, a major Clario acquisition, higher debt and a larger goodwill/intangible asset
OpenThermo Fisher Capital Allocation: Does Their Services Ecosystem Outperform Agilent CrossLab Strategy?
Thermo Fisher and Agilent both use service ecosystems, but capital allocation decides which model compounds better.
OpenThermo Fisher: the lab-tools compounder still has to prove the biopharma cycle is healing
Thermo Fisher reported 2025 revenue of $44.6 billion and Q1 2026 revenue of $11.0 billion. The thesis depends on biopharma demand, instrument and consumables mix, diagnostics normalization, margin durability, M&A integration and cash conversion.
Open